{"id":52108,"date":"2022-12-19T07:02:57","date_gmt":"2022-12-19T06:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/"},"modified":"2022-12-19T07:02:57","modified_gmt":"2022-12-19T06:02:57","slug":"sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/","title":{"rendered":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Sanofi gains exclusive license to Innate\u2019s B7H3 ANKET<sup>TM<\/sup> program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization<\/i><\/b>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Innate to receive \u20ac25m upfront and up to \u20ac1.35bn in total milestones plus royalties from Sanofi<\/i><\/b>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate\u2019s ANKET<sup>TM<\/sup> (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET<sup>TM<\/sup> targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.\n<\/p>\n<p>\nInnate and Sanofi signed a first <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fnode%2F2150&amp;esheet=53084141&amp;newsitemid=20221218005037&amp;lan=en-US&amp;anchor=NK+cell+engagers+collaboration&amp;index=1&amp;md5=88d9d76b647d3bc75395b969c48a9eda\" rel=\"nofollow noopener\" shape=\"rect\">NK cell engagers collaboration<\/a> in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi\u2019s R&amp;D team, with one of these molecules already in clinical studies.\n<\/p>\n<p>\n<b>Valeria Fantin, Ph.D., Global Head of Oncology Research at Sanofi<\/b>\n<\/p>\n<p>\n<i>\u201cAt Sanofi, we are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy. Our relationship with Innate aligns with our commitment to work with promising French companies and supports our ambition to develop a diverse portfolio of next-generation NK cell engagers, highly synergistic with Sanofi\u2019s allogeneic NK cell platform, engineered lymphokines that stimulate NK cells, and growing Immuno-oncology pipeline. As a leading global company with roots in France, we are proud to collaborate to support the French healthcare ecosystem.\u201d<\/i>\n<\/p>\n<p>\n<b>Yannis Morel, Ph.D., Executive Vice President, Product portfolio strategy &amp; Business development at Innate Pharma<\/b>\n<\/p>\n<p>\n<i>\u201cBuilding on the success of our existing collaboration on hematologic targets, we are pleased to expand and strengthen our partnership with Sanofi on NK Cell Engagers with the addition of up to three new programs, including in solid tumors. Sanofi\u2019s investment in Innate further validates the value of our ANKET<sup>TM<\/sup> platform and its potential to address multiple tumor types. By incorporating various tumor antigen binders, NK Cell Engagers are a versatile technology that may provide new options for patients and offer clinical benefit across multiple cancers, whilst also maintaining a good safety profile. This agreement also highlights Innate\u2019s strategy to build a broad portfolio of ANKET programs addressing different types of cancer.\u201d<\/i>\n<\/p>\n<p>\nUnder the terms of the new license agreement, Innate will receive \u20ac25m upfront payment and up to \u20ac1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales. Closing of the transaction is subject to HSR approval.\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>About ANKET<sup>TM<\/sup><\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fscience%2Four-nk-cell-engager-platform&amp;esheet=53084141&amp;newsitemid=20221218005037&amp;lan=en-US&amp;anchor=ANKETTM&amp;index=2&amp;md5=7057bd6791dfd172ef39e3a634f15f78\" rel=\"nofollow noopener\" shape=\"rect\">ANKET<sup>TM<\/sup><\/a> (Antibody-based NK cell Engager Therapeutics) is Innate&#8217;s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.\n<\/p>\n<p>\nThis versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.\n<\/p>\n<p>\nOur latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.\n<\/p>\n<p>\n<b>About 2016 Sanofi\/Innate research collaboration and licensing agreement<\/b>\n<\/p>\n<p>\nIn 2016, Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi\u2019s proprietary bispecific antibody format as well as tumor targets.\n<\/p>\n<p>\nA Phase 1\/2 clinical trial by Sanofi is ongoing, evaluating IPH6101\/SAR\u2019579 (SAR443579), the first NKp46\/CD16-based CD123-targeted ANKET<sup>TM<\/sup> NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).\n<\/p>\n<p>\nIn the summer 2022, Sanofi had made the decision to progress IPH6401\/SAR\u2019514 (SAR445514) into investigational new drug (IND)-enabling studies. IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE\u00ae multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate\u2019s ANKET<sup>TM<\/sup> proprietary platform.\n<\/p>\n<p>\nUnder the terms of the original license agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to \u20ac400m in development and commercial milestone payments as well as royalties on net sales. To date, \u20ac13m milestone payments to Innate have been announced.\n<\/p>\n<p>\n<b>About Sanofi\u2019s approach to NK therapies in oncology<\/b>\n<\/p>\n<p>\nAt Sanofi, we are exploring the intrinsic abilities of Natural Killer cells to create new immunotherapies for patients with cancer. Natural Killer cell-based therapies are a key pillar within Sanofi\u2019s Oncology strategy. By activating the innate power of NK cells, Sanofi is advancing a diverse and complementary range of NK-based therapeutics to transform immune biology. The breadth of our modalities and unique strength to innovate end-to-end maximizes the therapeutic possibilities for more people with cancer.\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>About Sanofi<\/b>\n<\/p>\n<p>\nWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people\u2019s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.\n<\/p>\n<p>\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY\n<\/p>\n<p>\n<b>About Innate Pharma<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.\n<\/p>\n<p>\nInnate Pharma\u2019s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.\n<\/p>\n<p>\nInnate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A\/S, Sanofi, and a multi-products collaboration with AstraZeneca.\n<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=53084141&amp;newsitemid=20221218005037&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=187b902eb8db5cb46899671435d9c61e\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a>\n<\/p>\n<p>\n<b>Information about Innate Pharma shares:<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b><br \/><b>Ticker code<\/b><br \/><b>LEI<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421\n<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Disclaimer on forward-looking information and risk factors:<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts, the Company\u2019s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company\u2019s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53084141&amp;newsitemid=20221218005037&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=4&amp;md5=a4b4420f5e4d9d79f66a166919a568c0\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Innate Pharma<\/b><br \/><b>Media Relations<\/b><br \/><b>Arthur Rouill\u00e9<\/b> | +33 1 44 71 00 15 | <a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#105;&#x6e;&#x6e;a&#116;&#x65;&#64;&#110;&#x65;&#x77;c&#97;&#x70;&#46;&#101;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">in&#110;&#97;&#116;&#x65;&#x40;&#x6e;&#x65;&#x77;ca&#112;&#46;&#101;&#x75;<\/a>\n<\/p>\n<p>\n<b>Investors Relations<\/b><br \/><b>Henry Wheeler<\/b> | +33 (0)4 84 90 32 88 | <a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;t&#x6f;&#58;&#x68;&#101;n&#x72;&#121;&#x2e;&#119;h&#x65;&#101;&#x6c;&#x65;r&#x40;&#105;n&#x6e;&#97;&#x74;&#101;-&#x70;&#104;&#x61;&#114;m&#x61;&#46;&#x66;&#x72;\" rel=\"nofollow noopener\" shape=\"rect\">henr&#121;&#46;&#119;&#104;&#101;&#x65;&#x6c;&#x65;&#x72;&#x40;&#x69;&#x6e;nate&#45;&#112;&#104;&#97;&#114;&#x6d;&#x61;&#x2e;&#x66;&#x72;<\/a>\n<\/p>\n<p>\n<b>Sanofi<\/b><br \/><b>Media Relations<\/b><br \/><b>Sandrine Guendoul<\/b><i> <\/i>| + 33 6 25 09 14 25 |<i> <\/i><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x73;&#x61;&#110;dr&#x69;&#x6e;&#x65;&#46;&#103;u&#x65;&#x6e;&#x64;&#111;&#117;l&#x40;&#x73;&#x61;&#110;&#111;fi&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#115;&#97;&#x6e;d&#114;&#x69;&#x6e;e&#46;&#x67;&#x75;e&#110;&#x64;&#x6f;u&#108;&#x40;&#x73;a&#110;&#x6f;&#x66;i&#46;&#x63;o&#109;<\/a><br \/><b>Sally Bain <\/b>| + 1 617 834 6026 | <a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;s&#97;&#x6c;&#x6c;y&#46;&#x62;&#x61;i&#110;&#x40;&#x73;a&#110;&#x6f;&#x66;i&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#97;l&#x6c;&#121;&#46;&#x62;&#97;i&#x6e;&#64;s&#x61;&#110;o&#x66;&#x69;&#46;&#x63;&#x6f;&#109;<\/a><br \/><b>Kate Conway <\/b>| + 1 508 364 4931 | <a target=\"_blank\" href=\"&#109;a&#105;l&#116;o&#x3a;k&#x61;t&#x65;&#46;&#x63;o&#x6e;w&#x61;y&#x40;s&#x61;n&#x6f;f&#x69;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#107;&#x61;&#x74;e&#46;&#x63;&#x6f;n&#119;&#x61;y&#64;&#x73;&#x61;n&#111;&#x66;i&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<p>\n<b>Investor Relations<\/b><br \/><b>Eva Schaefer-Jansen <\/b>| + 33 7 86 80 56 39 | <a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x65;&#x76;&#97;&#x2e;&#x73;&#99;&#x68;&#x61;&#101;&#x66;&#x65;&#114;&#x2d;&#x6a;&#97;&#x6e;&#x73;&#101;&#x6e;&#x40;s&#x61;&#x6e;o&#x66;&#x69;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">e&#118;&#x61;&#x2e;s&#99;&#x68;&#x61;e&#102;&#101;&#x72;&#x2d;j&#97;&#x6e;&#x73;e&#110;&#x40;&#x73;a&#110;&#111;&#x66;&#x69;&#46;&#99;&#x6f;&#x6d;<\/a><br \/><b>Arnaud Del\u00e9pine <\/b>| + 33 6 73 69 36 93 | <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#x61;&#114;&#x6e;&#x61;&#117;d&#x2e;&#100;e&#x6c;&#x65;&#112;&#x69;&#x6e;&#101;&#64;&#x73;&#97;n&#x6f;&#x66;&#105;&#x2e;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#97;r&#x6e;a&#x75;&#100;&#x2e;&#100;&#x65;&#108;e&#x70;i&#x6e;&#101;&#x40;&#115;&#x61;&#110;&#x6f;&#102;i&#x2e;c&#x6f;&#109;<\/a><br \/><b>Corentine Driancourt <\/b>| + 33 6 40 56 92 21 | <a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#99;&#x6f;&#x72;e&#110;&#x74;i&#110;&#x65;&#x2e;d&#114;&#x69;a&#110;&#x63;&#x6f;&#117;&#114;&#x74;&#64;&#115;&#x61;&#x6e;&#111;&#x66;&#x69;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x6f;&#x72;&#x65;&#x6e;&#x74;&#x69;&#x6e;&#101;&#46;&#100;&#114;&#105;&#97;&#110;cour&#x74;&#x40;&#x73;&#x61;&#x6e;&#x6f;&#x66;&#x69;&#x2e;&#99;&#111;&#109;<\/a><br \/><b>Felix Lauscher <\/b>| + 1 908 612 7239 | <a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#102;&#x65;&#x6c;i&#120;&#46;&#x6c;&#x61;us&#99;&#x68;&#x65;&#x72;&#64;&#115;&#x61;&#x6e;&#x6f;f&#105;&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#102;e&#x6c;i&#x78;&#46;&#x6c;a&#x75;&#115;&#x63;&#104;&#x65;&#114;&#x40;&#115;a&#110;o&#x66;i&#x2e;c&#x6f;&#109;<\/a><br \/><b>Priya Nanduri <\/b>| +1 617 764 6418 | <a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;&#111;&#x3a;&#112;&#x72;&#105;y&#x61;&#46;&#x6e;&#97;&#x6e;&#100;&#x75;&#114;&#x69;&#64;s&#x61;n&#x6f;&#102;&#x69;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x69;&#x79;&#x61;&#x2e;&#x6e;&#x61;&#x6e;&#x64;&#x75;&#x72;&#x69;&#x40;&#x73;&#x61;&#x6e;&#x6f;&#x66;&#x69;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/><b>Nathalie Pham <\/b>| + 33 7 85 93 30 17 | <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#110;a&#x74;&#104;a&#x6c;&#105;e&#x2e;&#x70;h&#x61;&#x6d;&#64;&#x73;&#x61;&#110;&#x6f;&#x66;&#105;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">n&#97;&#116;&#x68;&#x61;&#x6c;i&#101;&#46;&#x70;&#x68;&#x61;m&#64;&#115;&#x61;&#x6e;&#x6f;fi&#46;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi gains exclusive license to Innate\u2019s B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization Innate to receive \u20ac25m upfront and up to \u20ac1.35bn in total milestones plus royalties from Sanofi MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52108","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Sanofi gains exclusive license to Innate\u2019s B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization Innate to receive \u20ac25m upfront and up to \u20ac1.35bn in total milestones plus royalties from Sanofi MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-19T06:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology\",\"datePublished\":\"2022-12-19T06:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/\"},\"wordCount\":1501,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221218005037\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/\",\"name\":\"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221218005037\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2022-12-19T06:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221218005037\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221218005037\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend","og_description":"Sanofi gains exclusive license to Innate\u2019s B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization Innate to receive \u20ac25m upfront and up to \u20ac1.35bn in total milestones plus royalties from Sanofi MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-19T06:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology","datePublished":"2022-12-19T06:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/"},"wordCount":1501,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/","url":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/","name":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2022-12-19T06:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221218005037\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52108"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52108\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}